New treatments targeting a cancer-related protein
Novel TYRO3 inhibitors for treatment of cancer
This study is working on new medicines that target a protein called TYRO3, which helps cancer grow and resist treatment, and it aims to find out if these medicines can effectively kill cancer cells and boost the immune system in certain types of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11059055 on NIH RePORTER |
What this research studies
This research focuses on developing novel inhibitors for a protein called TYRO3, which is found in various cancer cells and contributes to tumor growth and resistance to treatments. By using advanced techniques like computational drug design and laboratory assays, the team aims to create effective drugs that can directly kill cancer cells and enhance the body's immune response against tumors. The research will test these inhibitors in specific cancer models to evaluate their effectiveness and safety.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults over 21 years old with advanced cancers such as leukemia, bladder cancer, or breast cancer.
Not a fit: Patients with early-stage cancers or those not expressing the TYRO3 protein may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve treatment outcomes for patients with advanced cancers.
How similar studies have performed: Previous research has shown promise in targeting similar proteins in cancer therapy, indicating potential for success with this approach.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Wang, Xiaodong — Univ of North Carolina Chapel Hill
- Study coordinator: Wang, Xiaodong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.